Skip to content
Syntara
A clinical‐stage drug development company primarily focused on blood related cancers.
SyntaraSyntara
  • Welcome
  • People
    • Board
    • Management
  • Pipeline
  • Clinical Trials
  • Investors
    • Investors home page
    • ASX Announcements
    • Quarterly Reports
    • Annual & Half-Yearly Reports
    • Investor Presentations
    • Media
    • Conference Posters
    • Analyst Reports
    • Shareholders
    • Shareholder Services
    • Corporate Governance
  • Contact
  • Welcome
  • People
    • Board
    • Management
  • Pipeline
  • Clinical Trials
  • Investors
    • Investors home page
    • ASX Announcements
    • Quarterly Reports
    • Annual & Half-Yearly Reports
    • Investor Presentations
    • Media
    • Conference Posters
    • Analyst Reports
    • Shareholders
    • Shareholder Services
    • Corporate Governance
  • Contact

Syntara (ASX: SNT) Presentation | NWR Virtual Healthcare Conference

You are here:
  1. Home
  2. Uncategorized
  3. Syntara (ASX: SNT) Presentation |…

Share

Linkedin
Ask me anything

Submit

Your question will be sent privately to Syntara Therapeutics. The company may choose to make this question public.

Highlights

Preliminary analysis of SNT-4728 iRBD Phase 2 study results provides encouraging signs of reduced brain inflammation

Read More »

SNT-9465 hypertrophic skin scarring trial exceeds 50% recruitment

Read More »

Investor Update Webinar

Read More »

Subscribe to our news

Subscribe

Syntara is a clinical stage drug development company focused on haematological malignancies.

Linkedin

ABN 75 082 811 630

Quick Links
  • Pipeline
  • Investors
  • Highlights
  • Pipeline
  • Investors
  • Highlights
Subscribe to our News
Get In Touch
  • Locked Bag 5015 
    Frenchs Forest 
NSW 2086
    AUSTRALIA
  • info@syntaratx.com.au 
  • +61 2 8760 1480

2026 © Syntara Limited.

Legal

Go to Top